Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab for pyoderma gangrenosum
ACTRN12623000211662Phase 2Completed
- Sponsor
- Royal Liverpool University Hospital
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tildrakizumab in pyoderma gangrenosum (PG), sponsored by Royal Liverpool University Hospital. Primary endpoint: Alterations in gene expression profiling and inflammatory cell counts in skin biopsy. Started Mar 2023; status: completed.
02
Drugs
tildrakizumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on ACTRN12623000211662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000211662.